News article: When science fiction becomes science fact – AI for rare disease diagnosis
The idea that an AI system could detect a disease that appears nowhere in a patient’s medical record sounds like something from speculative fiction. At Volv Global, it is something we do today. In brief Volv Global is featured in The Biopôle Review, published by Biopôle Lausanne, as part of an exploration of how science […]
Steroids Are the Red Flag in IBD Care That We Keep Ignoring
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Inflammatory Bowel Disease (IBD) management has evolved significantly with advanced therapies and data-driven care strategies. Yet, one persistent issue continues to undermine treatment outcomes: repeated steroid use. While steroids provide short-term relief, their recurring use often signals deeper inefficiencies in care pathways, delayed treatment optimisation, and […]
Advocacy in rare disease: Driving technology advances – 2023 Webinar
Introduction Advocacy plays a critical role in accelerating progress in rare diseases. As technology advances, collaboration between patient communities, researchers, healthcare systems, and innovators becomes essential to shorten diagnostic delays and ensure scientific breakthroughs translate into real patient benefit. This webinar discussion brought together experts from across healthcare, policy, and industry to explore how data […]
Chronic Obstructive Pulmonary Disease: Why We Need Better Patient Identification for 21st-Century Treatments
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: COPD as a “Syndrome,” Not Just One Disease Chronic Obstructive Pulmonary Disease (COPD) is often described as “smoker’s lung,” but modern guidelines now define it as a heterogeneous lung condition caused by damage to the airways and/or air sacs (emphysema) from different risk factors, […]
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: A Silent Disease Becoming a Public Health Emergency Metabolic dysfunction–associated steatohepatitis (MASH), historically known as non-alcoholic steatohepatitis (NASH), has rapidly shifted from an obscure hepatology concern to one of the fastest-growing causes of advanced liver disease worldwide. Around one-third of adults globally are estimated […]
Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Knowing When To Treat – AI for Transformation, Infection Risk, and Adaptive CLL Care Introduction: the long arc of CLL and its inflection risks Most people who have been diagnosed with chronic lymphocytic leukaemia (CLL) have no symptoms initially and are usually advised that no […]
Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes For decades, Type 1 Diabetes (T1D) has been managed reactively, diagnosed only once symptoms appear. And often, only at a crisis point, marked by diabetic ketoacidosis or severe hyperglycaemia. While insulin therapy has saved millions […]
News Article: AI in healthcare
Introduction Artificial intelligence continues to push healthcare into a new era from early disease detection to large-scale data modelling. Yet expectations often move faster than real-world progress. This interview explores a grounded, data-centric perspective from Christopher Rudolf, Founder & CEO of Volv Global, who warns that while AI holds enormous potential, the healthcare sector must […]
Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency View now: scroll down to watch the recording Discover how Volv Global, in collaboration with Takeda, Cleveland Clinic, and Komodo, applied AI-driven insights from real-world data (RWD) to rapidly identify previously undiagnosed alpha-1 […]
Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Recently, I had powerful thought come to me on reading an article about harnessing predictive modelling to overcome clinical trial enrolment challenges. The article is not wrong.[1] It is true that, by analysing real-time data streams on clinical trial recruitment performance, researchers can identify trends […]